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Summary 
Cyclin B is degraded at the onset of anaphase by a 
ubiquitin-dependent proteolytic system. We have frac- 
tionated mitotic Xenopus egg extracts to identify com- 
ponents required for this process. We find that UBC4 
and at least one other ubiquitin-conjugating enzyme 
can support cyclin B ubiquitination. The mitotic speci- 
ficity of cyclin ubiquitination is determined by a 20S 
~omplex that contains homologs of budding yeast 
CDC16 and CDC27, Because these proteins are re- 
quired for anaphase in yeast and mammalian cells, we 
refer to this complex as the anaphase-promoting com- 
plex (APC). CDC27 antibodies deplete APC activity, 
while immunopurified CDC27 complexes are sufficient 
to complement either interphase extracts or a mixture 
of recombinant UBC4 and the ubiquitin-activating en- 
zyme El. These results suggest that APC functions as 
a regulated ubiquitin-protein ligase that targets cyclin 
B for destruction in mitosis. 
Introduction 
Entrance into mitosis is governed by the protein kinase 
Cdc2, whose positive regulatory subunits, the mitotic 
cyclins, accumulate throughout interphase. Exit from mito- 
sis requires the inactivation of Cdc2, initiated by rapid 
cyclin B proteolysis that commences at anaphase. Resta- 
bilization in the subsequent interphase enables cyclin B 
to accumulate again, initiating a new mitotic cycle. In the 
embryonic ell cycle, the regulated activation and inactiva- 
tion of mitotic cyclin destruction transforms continuous 
cyclin synthesis into alternating periods of interphase and 
mitosis (reviewed by Nasmyth, 1993; King et al., 1994). 
Mitotic cyclins contain a short N-terminal sequence, 
called the destruction box (D box), that is required for their 
rapid degradation (Glotzer et a!., 1991). Ectopic expres- 
sion of nondegradable cyclins arrests the cell cycle with 
elevated levels of Cdc2 kinase activity (Murray et al., 1989; 
Ghiara et al., 1991; Luca et al., 1991; Gallant and Nigg, 
1992). This arrest occurs in telophase, suggesting that 
*These authors contributed equally to this work. 
cyclin degradation is required to exit mitosis (Surana et 
al., 1993; Holloway et al., 1993). Treatments that interfere 
with the proteolysis of endogenous cyclin B, however, ar- 
rest cell division earlier, at anaphase (Holloway et al., 
1993). This discrepancy can be explained by hypothesiz- 
ing that chromosome segregation and cyclin proteolysis 
depend upon common components. Support for this idea 
has emerged recently from studies in budding yeast, in 
which CDC16 and CDC23, genes required for progression 
through anaphase, have been shown to be required for 
the proteolysis of B-type cyclins (Irniger et al., 1995 [this 
issue of Cell]). The proteins encoded by these genes form 
a complex with the CDC27 protein (Lamb et al., 1994), a 
homolog of which is also required for anaphase progres- 
sion in mammalian cells (Tugendreich et al., 1995 [this 
issue of Cell]). 
Biochemical evidence suggests that cyclin proteolysis 
is mediated by the ubiquitin pathway: cyclin B-ubiquitin 
conjugates can be observed in mitotic, but not interphase, 
Xenopus extracts (Glotzer et al., 1991); mutations in the 
D box that block degradation also interfere with ubiquitina- 
tion (Glotzer et al., 1991); and methylated ubiquitin, an 
inhibitor of polyubiquitin chain formation, interferes with 
the proteolysis of A- and B-type cyclins in extracts of clam 
eggs (Hershko et al., 1991). 
A complex multistep athway is required for the covalent 
attachment of polyubiquitin chains to substrate proteins 
(reviewed by Ciechanover, 1994). The polypeptide ubiqui- 
tin is first activated at its C-terminus via thioester formation 
with El, the ubiquitin-acti~ating enzyme. E1 subsequently 
transfers ubiquitin to a family of ubiquitin-conjugating en- 
zymes (E2s), again forming thioester intermediates. Al- 
though certain E2s can transfer ubiquitin directly to sub- 
strates in vitro, the physiologic reaction often requires a 
third component, termed a ubiquitin-protein ligase or E3. 
This component can directly mediate substrate specificity 
and may also be required to synthesize the polyubiquitin 
chain that is presumed to target he substrate for degrada- 
tion by the 26S proteasome complex (reviewed by Peters, 
1994). In certain cases, substrate specificity is mediated 
by an additional component, such as the human papillo- 
mavirus E6 protein, which interacts with a cellular E3 to 
ubiquitinate p53 (Scheffner et al., 1993). 
The cyclin ubiquitination reaction is unusual in that it 
exhibits specificity at two levels: substrate recognition, 
which is reflected in the requirement for an intact D box, 
and temporal control in the limitation of its activity to a 
specific phase of the cell cycle, late mitosis and early G1 
(Hunt et al., 1992; Amon et al:,, 1994). Little is known re- 
garding the components involved in cyclin B ubiquitina- 
tion. Studies in budding yeast have implicated a ubiquitin- 
conjugating enzyme, UBC9, in the degradation of both S 
and M phase cyclins (Seufert et al., 1995); however, it 
remains unclear whether this enzyme is required for D 
box-dependent ubiquitination. Fractionation of clam egg 
extracts has separated two activities distinct from E1 that 
are required for cyclin ubiquitination (Hershko et al., 1994). 
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Figure 1. Fractionation of Cyclin Ubiquitination Activity in Mitotic 
Xenopus Egg Extracts into a Regulated and an Unregulated Fraction 
(A) Fractionation scheme. For details see Results. 
(13) Pellet (P), membrane (M), and supernatant ($100) fractions ob- 
tained from mitotic extracts were assayed for their ability oconvert 
a radiolabeled N-terminal fr gment of cyclin B ([1251]cyc) into ubiquitin 
conjugates. 
(C) Flowthrough (Q1) and eluate (Q2) fractions were obtained from 
mitotic $100 by Resource Q chromatography and assayed individually 
or after mixing equal volumes. D box dependence was tested by addi- 
tion of a radiolabeled fragment containing two D box point mutations 
(lane marked Q1 plus Q2 with an asterisk). 
(D) Flowthrough (Q1 ~) and eluate (Q2 i) fractions were prepared as in 
(C) using interphase $100 and were tested for their ability to replace 
Q1 and Q2 derived from mitotic $100. 
(El Fractions Q1 and Q2 were immunodepleted with either purified 
total mouse IgG control antibody (Q1 c and Q2 ~) or with purified MPM-2 
monoclonal antibody (Qlr" and Q2 m) and assayed as in (C). 
While one activity is found only in mitotic extracts, the 
other is active throughout he cell cycle and appears to 
be an E2. The components required for D box-dependent 
cyclin ubiquitination have not yet been molecularly iden- 
tified. 
We have fractionated mitotic Xenopus egg extracts to 
identify components required for cyclin B ubiquitination, 
We find at least two distinct E2s that are each sufficient 
to support cyclin B ubiquitination. Neither E2 is cell cycle 
regulated. We have identified one of these E2s as UBC4, 
an enzyme implicated in the ubiquitination of many pro, 
teins. We find that mitotic specificity is determined by a 
20S complex that contains homologs of the tetratricopep- 
tide repeat proteins CDC27 and CDC16. This complex, 
activated in mitosis, can act in conjunction with recombi- 
nant UBC4 and E1 to ubiquitinate cyclin B, suggesting 
that it functions as a temporally regulated cyclin-ubiquitin 
ligase. 
Results 
Cyclin Ubiquitination Activity Requires Both Cell 
Cycle-Regulated and Unregulated Fractions 
As a substrate for the cyclin ubiquitination reaction, an 
iodinated N-terminal fragment of sea urchin cyclin B was 
used. We monitored the formation of radiolabeled cyclin- 
ubiquitin conjugates by SDS-polyacrylamide gel electro- 
phoresis (SDS-PAGE) and autoradiography. The ubiquiti- 
nation and degradation of this protein are dependent upon 
the cell cycle state of crude extracts and require an intact 
D box (Holloway et al., 1993; data not shown). As a source 
of factors required for cyclin ubiquitination, concentrated 
interphase extracts from Xenopus eggs were prepared. 
Stable mitotic extracts that constitutively degrade cyclin 
B were then obtained by addition of the nondegradable 
cyclin B A90 fragment (Glotzer et al., 1991). 
Our fractionation protocol is shown sche m atically in Fig- 
ure 1A. As a first step, we prepared pellet, membrane, 
and supernatant ($100) fractions by high speed centrifu- 
gation of diluted crude mitotic extracts. Cyclin ubiquitina- 
tion activity was recovered in the $100 fraction after recon- 
centration to the original volume, as indicated by the 
ladder-like appearance of higher molecular mass species 
(Figure 1B). Ubiquitin conjugates were observed within 
1-2 min of incubation in the mitotic supernatant and 
reached a steady state within 5 min (data not shown). The 
substrate was degraded in this fraction with a half-life of 
5 rain, similar to that observed in crude extracts (data not 
shown). No ubiquitination activity was detectable in the 
washed pellet or membrane fractions (Figure 1B). 
We fractionated mitotic $100 by anion exchange chro- 
matography, using Resource Q as a resin, yielding a 
flowthrough fraction (Q1) and a 0.6 M KCI eluate (Q2). 
While neither fraction alone catalyzed cyclin ubiquitina- 
tion, mixing the fractions fully reconstituted activity (Figure 
1C). A substrate containing a mutated D box (R42A and 
A44R) produced only low molecular mass conjugates. To 
determine whether both of these fractions were mitotically 
regulated, we prepared Q1 and Q2 from interphase $100 
(designated Q1 ~ and Q2~). Cyclin ubiquitination was ob- 
sewed when Q1 was replaced by Q1 ~, but not when Q2 
was replaced by Q2 ~(Figure 1D), indicating that only Q2 
is mitotically regulated. 
We had observed that addition of the monoclonal anti- 
body MPM-2, which recognizes a phosphorylated epitope 
shared by a discrete number of mitotic phosphoproteins 
(Davis et al., 1983), could inhibit cyclin ubiquitination and 
degradation when added to crude mitotic extracts (J. 
Kuang, J, Penkala, M. Glotzer, R. W. K., and M. W. K, 
unpublished data). We found that immunodepletion of 
fraction Q2 with the MPM-2 antibody strongly inhibited 
cyclin ubiquitination, while depletion of fraction Q1 had 
no effect (Figure 1 E). Control depletions using total mouse 
immunoglobulin G (IgG) or an unrelated monoclonal anti- 
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Figure 2. Fraction Q1 Contains Two Distinct E2s That Are Each Suffi- 
cient to Support Cyclin Ubiquitination 
Fraction Q1 was subjected to Resource S chromatography, and the 
flowthrough (Q1A) and eluate (Q1B) fractions were analyzed by gel 
filtration. Elution volume (in milliliters) of each fraction is i dicated at 
the top of the figure. 
(A) Cyclin ubiquitination activity measured by addition of labeled cyclin 
([12Sl]cyc) N-terminus to each gel filtration fraction in the presence of 
an equal volume of Q2. 
(B) Thioester formation in each fraction was assayed by addition of 
E1 in the presence of radiolabeled ubiquitin ([1251]ub). 
(C) Immunoblot detection of UBC4 in each fraction. 
body were not inhibitory. This result further suggests that 
fraction Q2 is subject to mitotic regulation. 
Fraction Q1 Contains Two Distinct E2s That Each 
Supports Cyclin Ubiquitination 
To identify components in the unregulated fraction re- 
quired for cyclin ubiquitination, we further fractionated Q1 
by gel filtration and tested each fraction for its ability to 
complement Q2. We found complementing activity in a 
broad molecular mass range corresponding to 15-40 kDa, 
suggesting that multiple components in Q1 might each be 
sufficient o complement Q2 (data not shown). To test this 
idea, we fractionated Q1 by Resource S chromatography 
and generated a flowthrough fraction (Q1A) and a 0.6 M 
KCI eluate (Q1B). Each fraction was sufficient to comple- 
ment Q2 and was therefore further fractionated by gel 
filtration. The peak of activity in fraction Q1A eluted at 70 
ml, corresponding to a molecular mass of -30  kDa; activ- 
ity in fraction Q1B peaked at 81 ml, corresponding to - 20 
kDa (Figure 2A). The pattern of ubiquitin conjugates gener- 
ated by Q1A and Q1B was somewhat different: Q1A fa- 
vored the production of low molecular mass conjugates, 
whereas Q1B generated higher molecular mass conju- 
gates, suggesting that these two activities are distinct. 
Ubiquitination mediated by both Q1A and Q1B required 
an intact D box (data not shown). 
As ubiquitin-conjugating enzymes typically range in size 
from 14 to 28 kDa, we tested gel filtration fractions derived 
from Q1A and Q 1B for the presence of E2s by determining 






WT __  R42A,  A44R 
mend I:I~ (ZI Q 
B 
858 





1 oo ,' " .  
gg~ ,, .,' ..... . 
~~'~ ~o °' 
R8 ~ 
0 a 
o 25 50 7S 100 
Concentration (pg/ml) 
- '£}- -UBC2 
-e~UBC4 
Figure 3. Recombinant UBC4 Complements Fraction Q2 in D Box- 
Dependent Cyclin Ubiquitination 
(A) Recombinant purified human UBC2, human UBC4, and human 
CDC34 proteins (25 pg/ml each) were tested for their ability to comple- 
ment fraction Q2 in ubiquitination assays in which an N-terminal frag- 
ment of cyclin B,containing a wild-type (WT) or mutant (R42A, A44R) 
D box, was used as a substrate ([1251]cyc). 
(B) E2s (50 pg/ml each) were also tested for the ability to formthioesters 
with iodinated ubiquitin ([12Sl]ub) in the presence of El. The position 
of the El-ubiquitin thioester is indicated by an arrowhead. 
(C) Dose-response curve measuring the ability of UBC2 and UBC4 to 
complement fraction Q2. Conjugation was quantitated by phosphorim- 
ager analysis and is indicated in arbitrary units after subtraction for 
background. 
of radiolabeled ubiquitin and purified El .  Fraction QIA 
contained multiple ubiquitin thioesters of 24-34 kDa that 
copurified with cyclin ubiquitination activity (Figure 2B). 
By contrast, the activity in fraction Q1B copurified with a 
single predominant hioester of 22 kDa, suggesting the 
presence of a 15-16 kDa E2 (Figure 2B). As this thioester 
did not cofractionate with the peak of activity in fraction 
QIA, there appear to be at least two different E2s in frac- 
tion Q1 sufficient to complement fraction Q2. 
UBC4 Is Present in Fraction QIB, and Recombinant 
UBC4 Can Complement Fraction Q2 
Few E2s characterized to date would be expected to bind 
cation exchange resins like the activity in fraction Q1B. 
One of these, a Xenopus homolog of UBC9, did not cofrac- 
tionate with activity (R. W. K., J.-M. P., W. Seufert, S. 
Jentsch, and M. W. K., unpublished data). Another is rep- 
resented by the UBC4/UBC5 class of E2s in budding 
yeast, homologs of which have been found to bind cation 
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Figure 4. Fraction Q2 Contains E1 and a Mitotically Regulated Factor 
(A) Mitotic $100 derived from metaphase II-arrasted eggs was applied 
to a Resource Q column and eluted with a linear gradient from 100- 
600 mM KCI (corresponding tofractions 1-14). Fractions were de- 
salted and tested for ability to complement interphase $100 for cyclin 
ubiquitination activity (top) or were assayed for the presence of E1 
by addition of radiolabeled ubiquitin, followed by nonreducing SDS- 
PAGE (bottom; the El-ubiquitin thioester ismarked by an arrowhead). 
(B) Fraction 11 was tested for ability to complement interphase $100 
in the presence of wild-type or mutant (lane marked with asterisk) 
substrate or for ability to complement a mixture of recombinant El, 
UBC4, and purified ubiquitin. 
exchange resins (Girod and Vierstra, 1993; Scheffner et 
al., 1993). Fraction Q1B showed strong UBC4 immunore- 
activity that cofractionated with cyclin ubiquitination activ- 
ity during gel filtration, while fraction Q1A contained only 
a small amount of UBC4 that did not copurify with the 
majority of activity (Figure 2C). Therefore, we tested 
whether bacterially expressed and purified human UBC4 
was sufficient to complement fraction Q2. UBC4 sup- 
ported cyclin ubiquitination in a dose-dependent fashion 
(Figures 3A and 3C). Strong complementation was ob- 
served at 6 i~g/ml and was maximal at 25 i~g/ml (Figure 
3(3). Quantitative immunoblotting demonstrated that UBC4 
is present in fraction Q1 at a concentration of 4 i~g/ml (data 
not shown). A D box mutant yielded only low molecular 
mass conjugates in the presence of recombinant UBC4 
(Figure 3A), suggesting that substrate specificity is main- 
tained in this reconstituted system. Other purified E2s 
such as human CDC34 did not complement fraction Q2, 
even at high dosage; human UBC2 only weakly supported 
cyclin ubiquitination (Figures 3A and 3C). This was not 
due to a difference in the ability of these E2s to accept 
ubiquitin from El, because UBC2, UBC4, and CDC34 
formed similar amounts of ubiquitin thioesters (Figure 3B). 
Fraction Q2 Contains E1 and a Mitotically 
Regulated Factor 
Immunoblotting demonstrated the presence of E1 in frac- 
tion Q2 only (data not shown); its activity did not appear cell 
cycle regulated as both Q2 and Q2 ~ supported formation 
of a prominent -120 kDa El-ubiquitin thioester. Neither 
purified Xenopus E1 nor recombinant E1 was sufficient 
to complement fraction Q1, suggesting that Q2 contained 
additional components required for cyclin ubiquitination. 
To identify mitotically regulated components, we applied 
mitotic $100 to the Resource Q column and eluted it with 
Figure 5. The Mitotically Regulated Factor Is a 20S Complex Con- 
taining CDC27 and CDC16 
Fraction QE2 was refractionated byResource Q chromatography, and 
the peak of activity (designated L)was analyzed by sucrose gradient 
centrifugation a d assayed for ubiquitination activity in the presence 
of interphase $100 (top). Arrows indicate the positions of proteins 
sedimenting at10S and 15S, from left to right. Corresponding fractions 
were tested by immunoblotting for the presence of CDC27 and CDC16 
(middle and bottom, respectively). 
a linear 100-600 mM KCI gradient. Fractions were tested 
for their ability to complement interphase S 100, which pro- 
vided the nonmitotically regulated activities. El, as mea- 
sured by thioester formation with radiolabeled ubiquitin, 
eluted at - 200 mM KCI (Figure 4A, bottom). As expected, 
fractions containing E1 did not strongly complement in- 
terphase $100 (Figure 4A, top). Instead, the majority of 
the complementing activity eluted as a single peak at 400 
mM KCI (fraction 11). Formation of high molecular mass 
conjugates was substantially reduced when the D box mu- 
tant was assayed (Figure 4B). Significantly, fraction 11 
was also sufficient o complement a mixture of recombi- 
nant El, UBC4, and ubiquitin (Figure 4B), although the 
formation of high molecular mass conjugates was slightly 
reduced compared with the reaction using complete in- 
terphase $100. This result suggests that the mitotic factor 
functions as a mitosis-specific yclin-ubiquitin ligase and 
does not indirectly activate ubiquitination i the interphase 
$100 by converting it to a mitotic state. 
The Mitotically Regulated Factor Is a 20S Complex 
Containing Homologs of CDC27 and CDC16 
To characterize the stability of the mitotic activity, we pre- 
pared $100 fractions from different mitotic extracts and 
analyzed them by Resource Q chromatography. We com- 
pared cyclin B A90-activated extracts, metaphase II- 
arrested egg extracts, and extracts that had been incu- 
bated with ATP-y-S to thiophosphorylate mitotic phospho- 
proteins stably. In each case, interphase S100-comple- 
menting activity eluted at 400 m M KCI (Figure 4C; data not 
shown), indicating that the protocol used for preparation of 
mitotic extracts did not appreciably alter the chromato- 
graphic characteristics of the mitotic activity. Because 
thiophosphorylation is known to render mitotic phospho- 
proteins, such as MPM-2 antigens, resistant to dephos- 
phorylation (Kuang et al., 1991), we used thiophosphory- 
lated fractions in subsequent purification steps. 
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Figure 6. AComplexContainingCDC271sRequiredforUbiquitination 
Activity and Is Sufficient to Complement UBC4 and E1 
(A) Fraction QE2 was depleted with CDC27 antibodies (anti-CDC27) 
or control antibodies (preimmune) and was tested for ability to comple- 
ment interphase $100 (top). CDC27 and CDC16 proteins remaining 
after depletion were assayed by immunoblotting (middle and bottom, 
respectively). 
(B and C) CDC27 immunoprecipitates (CDC27-1P) or control immuno- 
precipitates (pre-IP) derived from fraction QE2 were assayed for the 
ability to complement either interphase $100 (B) or recombinant E1 
and UBC4 (C), using either wild-type or mutant (lane with asterisk) 
cyclin proteins. 
Thiophosphorylated mitotic extracts were fractionated 
on a fast flow Q column, yielding a high salt eluate that 
we refer to as fraction QE2. This fraction was reapplied 
to the Resource Q column, and proteins were eluted with 
a linear 100-600 mM KCI gradient. The peak of activity, 
eluting at 400 m M KCI, was further fractionated by sucrose 
gradient centrifugation. Figure 5 (top) indicates that in- 
terphase S100-complementing activity sedimented as a 
discrete complex of 20S-22S. Peak fractions could also 
complement a mixture of recombinant E1 and UBC4 (data 
not shown). Fractionation of the 400 mM Resource Q elu- 
ate over a Superose 6 column indicated an apparent mo- 
lecular mass between 1000 and 1500 kDa (data not 
shown). 
Recent work in yeast has shown that CDC16and CDC23, 
genes required for anaphase, are also necessary for the 
proteolysis of B-type cyclins in vivo (Irniger et al., 1995). 
Their protein products have been demonstrated to interact 
physically with the CDC27 protein (Lamb et al., 1994). In 
human cultured cells, CDC16 and CDC27 are components 
of a20S complex (S. T. and P. H., unpublished data). 
Therefore, we immunoblotted the sucrose gradient frac- 
tions with antibodies generated against human homologs 
of CDC16 and CDC27. Figure 5 (middle and bottom) indi- 
cates that CDC27 and CDC16 both cofractionated with 
activity. The corresponding preimmune s ra showed no 
reactivity (data not shown). Additional immunoblotting ex- 
periments revealed that both proteins also cofractionated 
with ubiquitination activity during Resource Q and gel fil- 
tration chromatography (data not shown). 
To determine whether CDC27 is required for ubiquitina- 
tion activity, we immunodepleted fraction QE2 with CDC27 
antibodies and assayed the supernatant for the ability to 
complement interphase $100. Figure 6A shows that 
CDC27 antibodies depleted activity, while preimmune 
sera had no effect. This treatment effectively removed 
both CDC27 and CDC16, suggesting that, as in yeast and 
humans, the two proteins form a complex. However, com- 
plete depletion of CDC16 required higher antibody con- 
centrations than were necessary to deplete CDC27 or ubi- 
quitination activity. CDC16 antibodies did not deplete 
CDC16, CDC27, or ubiquitination activity (data not 
shown). 
We next tested whether the CDC27 complex was the 
only mitotic component required for cyclin ubiquitination. 
Figure 6B demonstrates that stringently washed CDC27 
immunoprecipitates derived from fraction QE2 were suffi- 
cient to complement interphase $100, while control immu- 
noprecipitates were not. This activity required the pres- 
ence of an intact D box for generation of high molecular 
mass conjugates (Figure 6B). 
To determine whether the CDC27 immunoprecipitate 
contained cyclin-ubiquitin ligase activity, we assayed the 
mitotic immunoprecipitate against a defined system com- 
posed of recombinant El, UBC4, and purified ubiquitin. 
Figure 6C shows that a CDC27 immunoprecipitate com- 
plemented these components, while the control immuno- 
precipitate did not. Although the immunopurified CDC27 
complex retained some degree of D box dependence in 
this defined system (Figure 6C), the discrimination be- 
tween the wild-type and the mutant substrate was not as 
strong as when the immunoprecipitate was tested against 
interphase $100. The reduced specificity in the defined 
reaction is unlikely to be related to the use of purified 
UBC4, because the D box dependence of the reaction is 
fully maintained when UBC4 is used to complement otal 
fraction Q2 (see Figure 3A). Instead, this result may indi- 
cate that components required for full D box dependence 
may be partially lost during immunoprecipitation. 
Our sucrose gradient fractionation data and immunode- 
pletion experiments uggested that CDC27 and CDC16 
might be associated with one another in Xenopus extracts, 
as they are in yeast (Lamb et al., 1994). To test this possibil- 
ity directly, we analyzed CDC27 immunoprecipitates de- 
rived from either interphase $100 or fraction QE2 for the 
presence of CDC27 and CDC16. Figure 7A indicates that 
CDC27 immunoprecipitated from interphase $100 mi- 
grated as a 100 kDa protein on denaturing polyacrylamide 
gels. However, when derived from mitotic fraction QE2, 
CDC27 migrated as a 130-140 kDa protein, suggesting 
that it becomes modified in mitosis. Immunoblot analysis 
revealed that CDC16 coimmunoprecipitated with CDC27 
from both the interphase and mitotic fractions (Figure 7A). 
CDC16 derived from interphase $100 migrated as a 72 
kDa protein, while CDC16 derived from fraction QE2 was 
shifted to 74 kDa, indicating that it may also be modified 
in mitosis. These data suggest that at least a fraction of 
CDC16 is complexed with CDC27 during both interphase 
and mitosis. 
To determine the complexity of the CDC27 immunopre- 
cipitate, we incubated covalently coupled antibody beads 
in fraction QE2 and eluted bound proteins at low pH. Figure 
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Figure 7. CDC27 and CDC16 Are Associated in Both Interphase and 
Mitosis 
(A) Preimmune (Pre-IP) or CDC27 (CDC27-1P) immunoprecipitates de-
rived from either i nterphase $100 ($10~) or mitotic fraction QE2 were 
assayed by immunoblotting for the presence of either CDC27 or 
CDC16. The strongly reacting band at 55 kDa is IgG heaw chain 
derived from the immunoprecipitate. 
(13) Proteins in total fraction QE2 or proteins immunoprecipitated from 
this fraction were separated by SDS-PAGE, and the gels were ither 
stained with Coomassie blue or immunoblotted for the presence of 
CDC27 and CDC16. The positions of CDC27 and CDC16 in the immu- 
noblots are marked by a bracket and an arrowhead, respectively. Coo- 
massie blue-stained polypeptide bands that comigrated with CDC27 
and CDC16 have been indicated by the same symbols. The identity 
of the faster-migrating polypeptide band that cross-reacts with CDC27 
antibodies (lane 5) is presently unknown. 
7B shows that total fraction QE2 contained a large number 
of polypeptide bands as judged by Coomassie blue stain- 
ing. CDC27 immunoprecipitates derived from this fraction, 
however, yielded a discrete pattern of polypeptide bands 
that were not present in the control immunoprecipitate. 
Immunoblot analysis indicated that two of these bands 
comigrated with CDC27 and CDC16 (Figure 7B). The iden- 
tity of the other polypeptides is presently unknown, but 
their specific coimmunoprecipitation with CDC27 in 
roughly stoichiometric amounts suggests that they may 
represent additional components of the CDC27 complex. 
Discussion 
The proteolysis of mitotic cyclins is a key event in the cell 
cycle that irreversibly initiates exit from mitosis. Through 
the activation of Cdc2 kinase, a process is initiated that 
targets cyclins for destruction by the ubiquitin system. To 
determine the basis of the substrate and cell cycle specific- 
ity of cyclin ubiquitination, we have fractionated mitotic 
extracts to identify components required for this process. 
In addition to the universally required components E1 and 
ubiquitin, we have found three distinct activites that can 
reconstitute mitotic cyclin ubiquitination. The first two ac- 
tivities are a set of E2s that include UBC4; the third activity 
is a 20S complex that meets the functional criteria for a 
ubiquitin-protein ligase and appears to be the major deter- 
minant of cell cycle specificity in the cyclin ubiquitination 
system. Because this complex contains homologs of 
CDC27 and CDC16, proteins essential for the onset of 
anaphase, we refer to it as the anaphase-promoting com- 
plex (APC). 
Ubiquit in-Conjugating Enzymes Involved in Cyclin 
B Ubiquitination 
We find at least two ubiquitin-conjugating enzymes in 
Xenopus extracts that are each sufficient to complement 
APC and E1 to ubiquitinate cyclin B. Neither of these E2s 
appears to be responsible for the cell cycle specificity of 
cyclin ubiquitination. Both E2 activities support a D box- 
dependent reaction, suggesting that they act through a 
common recognition mechanism. Our data strongly sug- 
gest that one of the two E2 activities is a Xenopus homolog 
of UBC4. This protein copurifies with ubiquitination activity 
over ion exchange and gel filtration chromatography, and 
recombinant human UBC4 can fully complement D box- 
dependent cyclin ubiquitination at concentrations imilar 
to those found in our fractions. The second E2 activity in 
our fractions remains unidentified. This E2 has a higher 
apparent molecular mass than UBC4 and may correspond 
to the recently described activity in clam eggs called E-2C, 
for which sequence information has not yet been reported 
(Hershko et al., 1994). The Xenopus homolog of yeast 
UBC9, an enzyme implicated in cyclin degradation (Seuf- 
ert et al., 1995), does not cofractionate with either of our 
two E2 activities. 
UBC4 has been implicated in the degradation of many 
different proteins. In yeast it is required in conjunction with 
a closely related enzyme, UBC5, for the turnover of abnor- 
mal proteins (Seufert and Jentsch, 1990) and for the degra- 
dation of the MATa2 repressor (Chen et al., 1993). A U BC4 
homolog present in wheat germ extract appears capable 
of supporting ubiquitin conjugation to many proteins in 
vitro (Girod and Vierstra, 1993). Two mammalian homo- 
logs of UBC4 are capable of mediating the ubiquitination 
of p53 catalyzed by the E6-AP-E6 complex (Scheffner et 
al., 1994; Rolfe et al., 1995). The involvement of UBC4 in 
such varied ubiquitination reactions makes it an unlikely 
determinant of substrate specificity. Taken together with 
our data, these findings suggest that UBC4 may act in 
conjunction with multiple E3s. 
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Mutation of U BC4 family members in yeast has not been 
reported to cause a clearly defined cell cycle arrest (Seuf- 
ert and Jentsch, 1990). This could be due either to the 
pleiotropy of the mutation or to functional redundancy 
among E2s involved in cyclin ubiquitination. However, de- 
letion of UBC4 is synthetically lethal in yeast strains car- 
rying a temperature-sensitive mutation in CDC23 (Irniger 
et al., 1995), a potential component of APC, suggesting 
that these proteins function in the same biochemical 
pathway. 
APC Contains a Cell Cycle-Regulated 
Cyclin-Ubiquitin Ligase Activity 
Our data suggest that the cell cycle specificity of cyclin 
ubiquitination is mediated by APC, as this complex is the 
only mitotic component required to reconstitute cyclin 
ubiquitination in interphase fractions. The ability of APC 
to complement recombinant E1 and UBC4 indicates that it 
functions as a ubiquitin-protein ligase. We have identified 
two components of APC, CDC16 and CDC27. Our analysis 
of immunopurified APC indicates that it is likely to contain 
several additional subunits, consistent with its sedimenta- 
tion coefficient of 20S. One of these is likely to be a homo- 
log of CDC23, which has been demonstrated to interact 
physically with CDC16 and CDC27 in yeast (Lamb et al., 
1994). The findings that these proteins are required for 
cyclin degradation in yeast (Irniger et al., 1995) and for 
anaphase progression in fungi and mammalian cells (Hir- 
ano et al., 1988; O'Donnell et al, 1991; Tugendreich et al., 
1995) suggest that APC plays an essential role in cy- 
clin ubiquitination and anaphase progression in all eu- 
karyotes. 
We have not yet determined which of the subunits of 
APC is responsible for its ubiquitin-protein ligase activity. 
Two distinct types of E3s have been cloned thus far. Yeast 
UBR1 mediates N-end rule degradation (Bartel et al., 
1990); mammalian E6-AP participates in p53 ubiquitina- 
tion (Scheffner et al., 1993) and shares C-terminal homol- 
ogy with a family of other proteins that may also function 
as E3s (Scheffner et al., 1995). UBR1 and E6-AP do not 
share homology with each other or with CDC27, CDC16, 
or CDC23. Recently, it has been demonstrated that E6-AP 
can accept ubiquitin from UBC4, forming a thioester at 
a conserved cysteine residue essential for ligase activity 
(Scheffner et al., 1995). This E3-ubiquitin thioester may 
be the ultimate ubiquitin donor for the conjugation reac- 
tion. We have not yet been able to observe the formation 
of a similar ubiquitin thioester with any of the APC sub- 
units, but we have found that APC activity is sensitive 
to the sulfhydryl-reactive reagent N-ethylmaleimide (our 
unpublished data). 
While this manuscript was in preparation, Sudakin et 
al. (1995) reported a cell cycle-regulated activity of high 
molecular mass in clam extracts that is required for the 
ubiquitination of both A- and B-type cyclins. This activity 
may be related to the Xenopus APC; this should become 
clearer when molecular components of the clam activity 
have been identified. 
Regulation of APC 
The activation of cyclin B-Cdc2 kinase is required for the 
activation of cyclin degradation (Murray et al., 1989; Luca 
et al., 1991). Purified Cdc2 kinase triggers cyclin degrada- 
tion in interphase extracts (Felix et al, 1990); however, 
there is a 15 min lag period preceding activation, sug- 
gesting that the activation of APC by Cdc2 kinase may not 
be direct. Furthermore, the MPM-2 monoclonal antibody, 
which recognizes a discrete set of mitotic phosphopro- 
teins, can deplete APC activity from crude fractions (this 
paper) and can immunoprecipitate CDC27 and CDC16 
(our unpublished data). Phosphorylation of this epitope 
appears to be mediated, at least in part, by kinases distinct 
from Cdc2 (Kuang and Ashorn, 1993). These kinases pro- 
vide interesting candidates for regulators that function 
downstream of Cdc2 kinase to contribute to the activation 
of APC in mitosis. 
Immunoblotting experiments revealed that CDC27 un- 
dergoes a dramatic upward electrophoretic mobility shift 
during the course of mitotic activation. Preliminary experi- 
ments indicate that treatment of CDC27 immunoprecipi- 
tates with phosphatase can completely reverse this mobil- 
ity shift (S. T. and P. H., unpublished data), suggesting 
that altered mobility is a consequence of phosphorylation. 
Such large mobility shifts have been reported for other 
MPM-2 epitopes, such as Cdc25 (Kumagai and Dunphy, 
1992; Kuang et al., 1994). During the course of mitotic 
activation, the CDC27 upshift precedes the activation of 
cyclin ubiquitination, suggesting either a requirement for 
a threshold level of modification or the existence of addi- 
tional controls (our unpublished ata). Our immunoprecipi- 
tation results indicate that CDC27 and CDC16 are associ- 
ated in both mitosis and interphase, suggesting that an 
assembled but inactive form of APC may be present during 
interphase. 
A Common Set of Components for Cyclin 
Destruction and Anaphase: 
A Common Mechanism? 
Biochemical and genetic evidence has now converged to 
suggest that cyclin degradation and sister chromatid seg- 
regation are mediated by a common set of components 
including CDC16, CDC23, and CDC27. This complex may 
have functions in addition to cyclin ubiquitination, as cer- 
tain mutant alleles of CDC16 and CDC27 block anaphase 
progression but do not interfere with cyclin degradation 
(Irniger et al., 1995). One such function of this complex 
might be the ubiquitination of substrates other than mitotic 
cyclins whose degradation is required for the onset of ana- 
phase. The existence of such proteins is suggested by 
the finding that an N-terminal fragment of cyclin B can 
inhibit he onset of anaphase in extracts that contain only 
a nondegradable form of cyclin (Holloway et al., 1993). 
Furthermore, methylated ubiquitin interferes with sister 
chromatid separation, suggesting the involvement of ubiq- 
uitin-mediated proteolysis in this process. APC may there- 
fore ubiquitinate several proteins whose degradation is 
required for anaphase, explaining why some but not all 
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CDC16 al le les interfere with cyclin proteo lys is  in yeast.  
Alternat ively,  APC may have  funct ions that  are indepen-  
dent  of  its ub iqu i t in -prote in  l igase activity. 
Why the cyc l in -ub iqu i t in  l igase is conta ined  in such a 
large complex  is present ly  a mystery.  Some insight into 
this prob lem may be found in the observat ions  in fungi  
and mammal ian  cel ls that homologs  of  CDC27 and CDC16 
local ize to the mitotic sp ind le  and cent rosomes  (Mirabito 
and Morris,  1993; Tugendre ich  et al., 1995), structures 
that are also assoc ia ted  with MPM-2  ant igens  and cyclin 
B (Engle et al., 1988; Bai l ly et al., 1992; Ma ldonado-Cod ina  
and Glover,  1992; Vandre  et al., 1986). The  assoc iat ion 
of  APC with spindle components  may be important for the 
proper  regulation of anaphase,  perhaps by restraining APC 
activity until the chromosomes  are a l igned on the meta- 
phase  plate. On ly  then wou ld  the spindle s ignal  the activa- 
t ion of  APC,  init iating both cycl in proteolys is  and the segre-  
gat ion of  s ister chromat ids .  
Experimental Procedures 
Antibodies 
Rabbit serum raised against human UBC4 (Rolfe et al., 1995) was used 
at a dilution of 1:300 in immunoblotting experiments and recognized a 
major band of 15 kDa in Xenopus egg extract and in fraction Q1 that 
was absent from fraction Q2. Monoclonal E1 antibodies (1C5; 
Schwartz et al., 1992) were the gift of Dr. A. Schwartz (Washington 
University School of Medicine). Rabbit sera raised against human 
CDC27 and CDC16 (Tugendreich et al., 1995) were used for immu- 
noblotting at a dilution of 1:2000. Immunoblots were visualized using 
the ECL detection system (Amersham). 
Preparation of Extracts and High Speed Supernatants 
Interphase extracts were prepared as described elsewhere (Murray, 
1991), except thateggs were activated with the calcium ionophore 
A23187 (Calbiochem) at a concentration of 1 ixg/ml. Cycloheximide 
was added to arrest the extracts in interphase. To generate mitotic 
A90 extracts, we added a bacterially expressed nondegradable A90 
fragment of sea urchin cyclin B to interphase extracts at a concentra- 
tion of 60 p.g/ml. A different mitotic extract was prepared from nonacti- 
rated metaphase II-arrested eggs in the presence of 1 pM okadaic 
acid (Calbiochem) according to the protocol of Kuang et al. (1991). 
For the generation of high speed supernatants, extracts were diluted 
10-fold in buffer Q-A (20 mM Tris-HCI [pH 7.7], 100 mM KCI, 0.1 mM 
CaCI2, 1 mM MgCI2, 1 mM DTT) containing an energy-regenerating 
system (Murray, 1991) and 1 pM okadaic acid (mitotic extracts only) 
and were centrifuged for 1 hr at 115,000 x g. The supernatant was 
reconcentrated to 50% of the original extract volume in Centriprep-10 
concentrators (Amicon). Pellet and membrane fractions were sepa- 
rately resuspended in the dilution buffer, centrifuged again, and resus- 
pended in 50% of the original volume. The fractions were stored at 
-70oC. 
For preparation of fraction QE2, extracts from metaphase II- 
arrested eggs were thiophosphorylated using the protocol described 
by Kuang et al. (1991) with modifications (J. Kuang, C. Ashorn, M. 
Nelman-Gonzalez, T. Stukenberg, and M. W. K., unpublished data). 
Protein Fractionation 
Column chromatography was done with an FPLC system (Pharmacia) 
at 4°C. To generate fractions Q1 and Q2, we applied 20-40 ml of 
diluted $100 to a 6 ml Resource Q column equilibrated with Q-A. 
Proteins eluted with 0.5 M KCI in Q-A (Q2) were desalted on PD10 
columns (Pharmacia), and both the flowthrough (Q1) and Q2 fractions 
were reconcentrated to 50% of the original extract volume. 
To generate fractions Q1A and QIB, we precipitated Q1 derived 
from 50 ml of diluted $100 with 80% ammonium sulfate, redissolved 
and gel filtered into buffer S-A (10 mM PIPES-KOH [pH 6.5], 30 mM 
KCI, 1 mM DTT) and applied to a 6 ml Resource S column equilibrated 
with S-A. The flowthrough (QIA) and proteins eluted with 0.5 M KCI 
in S-A (Q1B) were gel filtered into buffer Q-A and reconcentrated. 
Because QIB prepared this way contained a small amount of the 30 
kDa activity, we raised the KCI concentration in buffer S-A during the 
S chromatography step to 50 mM and simplified the purification by 
applying $100 directly to the column. This protocol generated a Q1B 
fraction that was not contaminated with the activity found in Q1A. 
For analysis of Q1A and Q1B by gel filtration, we separated 1-2 
ml samples of concentrated Q1A or Q1B on a Superdex 75 column 
(125 ml) in buffer Q-A at a flow rate of 0.75 ml/min. Fractions of 5 ml 
were concentrated 10- to 25-fold. In some cases, ubiquitin or bovine 
serum albumin was added to the fractions to a final concentration of 
0.2 mg/ml before reconcentration. 
For further fractionation of Q2, 40 ml of diluted mitotic $100 was 
applied to the Resource Q column. Bound proteins were eluted with 
six column volumes of a linear salt gradient (0-500 mM KCI in Q-A). 
Fractions (2.5 ml) were collected, desalted, and reconcentrated to 0.5 
ml. Similar amounts of $100 prepared from metaphase II extracts or 
thiophosphorylated QE2 fractions were fractionated using the same 
protocol. 
To determine the S value of APC, we rachromatographed fraction 
QE2 over Resource Q, and the fraction containing APC was analyzed 
by sucrose gradient centrifugation (15%-40%) for 13.5 hr at 37,500 
rpm in an SW40 rotor (Beckman). Fractions (0.85 ml) were diluted 
1:4 with buffer Q-A and concentrated to 150 rd. The positions of the 
15S p97-ATPase (Peters et al., 1990) and a 10S complex of elongation 
factors (J.-M. P., unpublished data) separated in the same gradient 
were used as references. 
To determine the apparent molecular mass of APC, we applied 0.2 
ml of a reconcentrated Q column fraction to a 24 ml Superose 6 column 
at a flow rate of 0.5 ml/min. Fractions of 1 ml were reconcentrated to 
0.1 ml and assayed against interphase $100. 
Ubiquitination Assays 
An N-terminal fragment of sea urchin cyclin B, consisting of residues 
13-110, and a corresponding fragment containing a mutated D box 
(R42A and A44R; Holloway et al., 1993) were labeled to a specific 
activity of 100 i~Ci/~g using the chloramine T procedure. Ubiquitination 
assays were performed in a total volume of 5 p.I. They contained an 
energy-regenerating system, 1.25 mg/ml bovine ubiquitin (Sigma), 
12.5 ng (100 nM) of labeled substrate, 2-3 p~l of column fraction, and in 
some cases either 1.25 pl of interph ass $100 or 130 pg/ml recombinant 
human E1 and 25 p.g/ml recombinant human UBC4 (Rolfe et al., 1995). 
Reactions were incubated at 22°C for 10 rain; quenched by addition 
of SDS sample buffer, and analyzed by SDS-PAG E followed by autora- 
=~ diography or phosphorimaging. 
Thioester Assays 
For El-ubiquitin thioester assays, column fractions were incubated 
with 0.3 p.g of iodinated ubiquitin (10 p.Ci/pg) in a total volume of 10 
p.I in the presence of 5 mM Tris-HCI (pH 7.7), 10 mM MgCI2, 1 mM 
ATP, 0.1 mM DTT, and 1 U inorganic pyrophosphatase (Sigma). After 
5 rain at 22°C, reactions were stopped by addition of 10 pl of urea 
sample buffer (120 mM Tris-HCI [pH 6.8], 4O/o SDS, 4 M urea, 20% 
glycerol), and reaction products were analyzed by nonreducing SDS- 
PAGE and autoradiography. E2-ubiquitin thioester assays were per- 
formed as described, except that reaction mixtures contained either 
partially purified Xenopus E1 or purified recombinant human El. 
Immunodepletion and Reconstitution Experiments 
Purified monoclonal MPM-2 antibodies (Davis et al., 1983) were the 
gift of Dr. J. Kuang (University of Texas, Houston); 0.25 vol of MPM-2 
antibodies (10 mg/ml) or control antibodies (purified total mouse IgG 
[Sigma]; 10 mg/ml) were incubated with fraction Q1 or Q2 for 20 rain 
on ice in a final volume of 13.5 I~1. Protein A-Sepharose beads (5 Id; 
Sigma) were added, incubated on ice for 40 min, and subsequently 
removed by centrifugation. The supernatants were tested for ubiquiti- 
nation activity. 
To immunodeplete CDC27 from fraction QE2, we incubated 4 vol 
of anti-CDC27 or preimmune serum with 1 vol of protein A-Affiprep 
beads (Bio-Rad) for 2 hr at 4°C. Beads were washed five times in 
buffer Q-A, incubated in 2 vol of fraction QE2 for 2 hr at 4°C, and 
removed by centrifugation. 
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For reconstitution experiments, 0.5 vol of CDC27 antiserum or pre- 
immune antiserum was bound to 1 vol of protein A beads as described 
above. The beads were incubated with 5 vol of fraction QE2 for 2 hr 
at 4°C and subsequently washed five times in buffer Q-A containing 
500 mM KCI and three times in Q-A. For immunoblot analysis, the 
beads were eluted with SDS sample buffer. For ubiquitination assays, 
5 Id of washed beads was incubated with 6 p.I of reaction mix containing 
an energy-regenerating system, ubiquitin, and labeled substrate and 
either interphase $100 or a mixture of recombinant E1 (260 i~g/ml) 
and UBC4 (50 p.g/ml). 
To analyze the protein composition of the CDC27 immunoprecipi- 
tate, we bound antibodies to protein A beads as above and covalently 
coupled them using the dimethylpimelimidate method (Harlow and 
Lane, 1988). Of the immune and preimmune beads, 50 ILl each was 
incubated with 750 p.I of fraction QE2 for 2 hr at 4°C. Subsequently, 
the beads were washed five times in Q-A containing 500 mM KCI and 
0.5% NP-40, once in Q-A, and once in 10 mM KPO4 (pH 6.8). Bound 
proteins were eluted with 400 p.I of 100 mM glycine-HCI (pH 2.1). The 
eluate was neutralized, concentrated 10-fold, and analyzed by 
SDS-PAGE. 
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